$PRME News

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

Prime Medicine Gets FDA Green Light for Gene Editing Study

Prime Medicine stock surges on FDA IND clearance

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Prime Medicine to Participate in Upcoming Investor Conferences

BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?

Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug